Targeted chemo shows promise for tough prostate cancer
NCT ID NCT03652493
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 25 times
Summary
This study tested the chemotherapy drug carboplatin in 16 men with advanced prostate cancer that no longer responds to hormone therapy. The cancer had specific gene changes that might make it sensitive to this treatment. The goal was to see if carboplatin could shrink tumors or lower PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre François Baclesse
Caen, 14076, France
-
Centre Oscar Lambret
Lille, 59000, France
-
Chu Rouen
Rouen, 76000, France
-
Institut Gustave ROUSSy IGR
Villejuif, France
Conditions
Explore the condition pages connected to this study.